Expertise in
10
conditions

Ferhat Meziani

Strasbourg, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
10
conditions
Strasbourg, FR 

Overview

Ferhat Meziani practices practicing medicine in Strasbourg, France.

Meziani is highly rated in 10 conditions, according to our data. Their clinical expertise encompasses Sepsis, Disseminated Intravascular Coagulation, Acute Respiratory Distress Syndrome (ARDS), and Pneumonia.

They are actively involved in clinical research, co-authoring 151 peer reviewed articles and participating in 15 clinical trials.

Locations

Strasbourg, France
Other Locations
Lyon, 86000, France
Tours, France
Limoges, France
France
UMR 955 Eq 13, University Of Paris Est Créteil, Creteil, France
Paris, France
Dijon, France
Nimes, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock
Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock
Enrollment Status: Recruiting
Publish Date: August 05, 2025
Intervention Type: Drug
Study Drug: Levosimendan
Study Phase: Phase 3
Impact on Mortality of the Timing of Renal Replacement Therapy in Patients With Severe Acute Kidney Injury in Septic Shock: the IDEAL-ICU Study (Initiation of Dialysis Early Versus Delayed in the Intensive Care Unit): Study Protocol for a Randomized Controlled Trial
Impact on Mortality of the Timing of Renal Replacement Therapy in Patients With Severe Acute Kidney Injury in Septic Shock: the IDEAL-ICU Study (Initiation of Dialysis Early Versus Delayed in the Intensive Care Unit): Study Protocol for a Randomized Controlled Trial
Enrollment Status: Terminated
Publish Date: February 09, 2026
Intervention Type: Procedure
Study Phase: Phase 3
Effects of Low-dose Corticosteroids on Survival of Severe Community-acquired Pneumonia
Effects of Low-dose Corticosteroids on Survival of Severe Community-acquired Pneumonia
Enrollment Status: Completed
Publish Date: December 22, 2025
Intervention Type: Drug
Study Drug: Hydrocortisone
Study Phase: Phase 3
Early Versus Differed Arterial Catheterization in Critically Ill Patients With Acute Circulatory Failure: A Multicentre, Open-label, Pragmatic, Randomised, Non-inferiority Controlled Trial (EVERDAC Trial)
Early Versus Differed Arterial Catheterization in Critically Ill Patients With Acute Circulatory Failure: A Multicentre, Open-label, Pragmatic, Randomised, Non-inferiority Controlled Trial (EVERDAC Trial)
Enrollment Status: Completed
Publish Date: December 22, 2025
Intervention Type: Procedure
Study Phase: Not Applicable
Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion: a Randomized Controlled Multi-center Trial
Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion: a Randomized Controlled Multi-center Trial
Enrollment Status: Completed
Publish Date: November 21, 2025
Intervention Type: Drug
Study Drug: Dobutamine
Study Phase: Phase 3
A Randomized, Controlled, Open-labeled, Multi-center Clinical Trial to Evaluate the Safe and Effective Performance of the Lungpacer Diaphragm Pacing Therapy System in Patients Who Have Failed to Wean From Mechanical Ventilation.
A Randomized, Controlled, Open-labeled, Multi-center Clinical Trial to Evaluate the Safe and Effective Performance of the Lungpacer Diaphragm Pacing Therapy System in Patients Who Have Failed to Wean From Mechanical Ventilation.
Enrollment Status: Terminated
Publish Date: December 09, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double-blind, Placebo-controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients With Severe Pulmonary COVID-19 Related Disease
A Randomized, Double-blind, Placebo-controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients With Severe Pulmonary COVID-19 Related Disease
Enrollment Status: Completed
Publish Date: September 23, 2024
Intervention Type: Biological, Drug
Study Drugs: Otilimab, Standard of Care
Study Phase: Phase 2
Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults
Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Other, Drug
Study Drugs: Remdesivir, Lopinavir, Ritonavir, Interferon Beta-1A, Hydroxychloroquine, AZD7442
Study Phase: Phase 3
Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing
Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing
Enrollment Status: Completed
Publish Date: November 16, 2022
Intervention Type: Device
Study Phase: Not Applicable
Psychological Impact of the Hospitalization of a Family Member in Intensive Care for Covid-19 Infection
Psychological Impact of the Hospitalization of a Family Member in Intensive Care for Covid-19 Infection
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Other
View 9 Less Clinical Trials

151 Total Publications

Physiopathology of fibrinolysis in sepsis-induced disseminated intravascular coagulation: Emerging mechanisms and pharmacological targets.
Physiopathology of fibrinolysis in sepsis-induced disseminated intravascular coagulation: Emerging mechanisms and pharmacological targets.
Journal: Annals of intensive care
Published: March 06, 2026

Frequently Asked Questions about Ferhat Meziani

Is Ferhat Meziani a top-rated expert for Sepsis?

MediFind is an objective health platform that identifies experts based on real-world data. Ferhat Meziani is classified as an Distinguished expert for Sepsis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Ferhat Meziani participate in research or clinical trials?

Yes. Ferhat Meziani has published 151 articles and abstracts on conditions like Sepsis. You can view a list of Ferhat Meziani's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Meziani's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 16 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile